lystn

Neither Bloomberg's MaA executive editor Jeff McCracken nor host Alex Sherman can remember a deal quite like Johnson a Johnson's pursuit of Swiss drugmaker Actelion. First JaJ publicly stated it was in talks with Actelion. Then, JaJ said talks were over, and another party (Sanofi) had entered talks to buy Actelion. But just a week later, JaJ and Actelion announced they'd re-entered talks. Now Bloomberg reports the sides have reached a tentative agreement on price, and a deal may be announced before the end of the month. McCracken explains why Actelion is such a coveted asset and what other large health care deals may emerge in 2017.